This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock
by Zacks Equity Research
Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.
BioCardia (BCDA) Up on Plans for Second Heart Failure Study
by Zacks Equity Research
BioCardia (BCDA) completes enrollment in a pivotal phase III study on its CardiAMP cell therapy for the treatment of heart failure. It plans to begin a second study with responders from the initial study.
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Q2 Earnings Beat, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports narrower-than-expected loss for the second quarter of 2023. Qinlock drives year-over-year sales.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 8.06% and 5.42%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Up 3.6% Since Last Earnings Report?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Q1 Earnings Match Estimates, Sales Miss
by Zacks Equity Research
Deciphera Pharmaceuticals (DCPH) reports mixed first-quarter 2023 results as its earnings are in line with the Zacks Consensus Estimate, while revenues miss the same.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 0% and 5.10%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
by Zacks Equity Research
Ultragenyx (RARE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Deciphera Pharmaceuticals, Inc. (DCPH) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 7% Since Last Earnings Report?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
by Zacks Equity Research
The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.
Deciphera Pharmaceuticals, Inc. (DCPH) Soars 10.3%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 7.1% Since Last Earnings Report?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
by Zacks Equity Research
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Deciphera's (DCPH) Q4 Earnings Miss, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a wider-than-expected loss per share for the fourth quarter of 2022, while revenues driven by Qinlock sales, beat estimates.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of -5.26% and 2.59%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.
Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
Deciphera (DCPH) Issues Strategic & Corporate Outlook for 2023
by Zacks Equity Research
Deciphera (DCPH) provides a strategic outlook and planned corporate milestones for 2023. The company also posts preliminary fourth-quarter and 2022 revenues.
Deciphera's (DCPH) Q3 Loss Narrows, Qinlock Drives Revenues
by Zacks Equity Research
Deciphera (DCPH) reports a narrower-than-expected loss for the third quarter of 2022 while revenues beat estimates. Qinlock drives year-over-year sales.
Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) delivered earnings and revenue surprises of 3.51% and 8.07%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.
Will Ayvakit Aid Blueprint Medicines (BPMC) Amid Rivalry?
by Zacks Equity Research
Blueprint Medicines (BPMC) expects its lead drug, Ayvakit, which is approved to treat rare cancer and other rare diseases, to generate incremental sales and combat stiff competition.
Is Deciphera Pharmaceuticals (DCPH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Deciphera Pharmaceuticals, Inc. (DCPH) and Jazz Pharmaceuticals (JAZZ) have performed compared to their sector so far this year.